Clinical Trials Logo

Thyroid Neoplasms clinical trials

View clinical trials related to Thyroid Neoplasms.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06271044 Active, not recruiting - Clinical trials for to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm

a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS

Start date: October 2014
Phase: N/A
Study type: Interventional

To study if its is safe to reduce the amount of postoperative treatments in those patients, who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level.

NCT ID: NCT05796258 Active, not recruiting - Thyroid Cancer Clinical Trials

Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

NTRK
Start date: July 26, 2021
Phase:
Study type: Observational

This multi-center study aims at NTRK fusion testing of all patients with advanced thyroid cancer (any histotype and regardless of stage). The primary objective of this study is to assess the frequency of NTRK fusions in thyroid cancer. The secondary objective of this study is to develop an effective tool (testing) strategy for the detection of NTRK fusions in thyroid tumors, comparing the diagnostic tecniques available (IHC, real-time PCR and NGS).

NCT ID: NCT05696548 Active, not recruiting - Clinical trials for Anaplastic Thyroid Cancer

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Start date: July 2, 2019
Phase: Phase 2
Study type: Interventional

This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.

NCT ID: NCT05579782 Active, not recruiting - Thyroid Cancer Clinical Trials

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

Start date: October 5, 2022
Phase: N/A
Study type: Interventional

This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands during total thyroidectomy. It compares risk-benefits and outcomes in patients undergoing total thyroidectomy where NIRAF detection with PTeye for parathyroid identification is either used or not used.

NCT ID: NCT05241834 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Start date: March 23, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

NCT ID: NCT05102292 Active, not recruiting - Clinical trials for Anaplastic Thyroid Cancer

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Start date: December 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).

NCT ID: NCT05014698 Active, not recruiting - Clinical trials for Differentiated Thyroid Cancer

IDEntification of New Predisposition Genes in Differentiated THYroid Cancer

IDENTHY-K
Start date: February 23, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).

NCT ID: NCT05007093 Active, not recruiting - Clinical trials for DTC - Differentiated Thyroid Cancer

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.

NCT ID: NCT04970134 Active, not recruiting - Clinical trials for Medullary Thyroid Carcinoma

Spanish Study for Molecular Characterization of Thyroid Carcinoma

MOLTHY
Start date: June 14, 2021
Phase:
Study type: Observational

This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation. Three diagnostic techniques will be performed on formalin-fixed paraffin embedded (FFPE) tumor samples from the study population: immunohistochemistry (IHC), fluorescence by in situ hybridization (FISH) as well as Next-Generation Sequencing (NGS) techniques by means of DNA and RNA analysis (Ion Platform Torrent - Oncomine Focus Assay, 52 gene detection). The results of each patient will be compared in order to correlate the results of each method.

NCT ID: NCT04552769 Active, not recruiting - Thyroid Cancer Clinical Trials

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid